Upregulated cholesterol biosynthesis via SREBP2 promoted liver cancer stem cell (CSC) expansion and drug resistance, while simvastatin sensitized HCC cells to sorafenib.31 Here, SREBF2 is linked to hepatocellular carcinoma.